Abbott Laboratories $ABT Shares Acquired by Wedmont Private Capital

Wedmont Private Capital raised its holdings in Abbott Laboratories (NYSE:ABT) by 5.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,922 shares of the healthcare product maker’s stock after acquiring an additional 1,732 shares during the quarter. Wedmont Private Capital’s holdings in Abbott Laboratories were worth $4,119,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories during the 1st quarter valued at $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the first quarter valued at $28,000. Elequin Capital LP acquired a new stake in Abbott Laboratories during the first quarter worth approximately $30,000. Wormser Freres Gestion purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $32,000. Finally, JCIC Asset Management Inc. acquired a new position in Abbott Laboratories in the 1st quarter valued at $32,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

NYSE ABT opened at $133.90 on Thursday. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The stock’s 50-day moving average is $130.36 and its two-hundred day moving average is $131.24. The firm has a market cap of $233.05 billion, a P/E ratio of 16.78, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of research reports. Evercore ISI boosted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Leerink Partners began coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a “market perform” rating and a $143.00 price objective for the company. Morgan Stanley increased their target price on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and boosted their price target for the company from $143.00 to $145.00 in a report on Friday, July 18th. Finally, Royal Bank Of Canada increased their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a report on Tuesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $144.47.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.